First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

SuppVersity, 13 Jun 2013

Remember that the purported mechanism for the increased influx of glucose and correspondingly higher insulin levels in the…